Jury Awards $150 Million to Androgel® Victim
In the second trial involving Androgel a jury in the Northern District of Illinois awarded Jessee Mitchell $150 million in punitive damages. The jury, however, failed to award Mr. Mitchell any damages for his personal injury. The jury found that the Androgel label was adequate.
The substantial jury award will be viewed as a win for the thousands of Androgel users who suffered serious injuries while using Androgel and who are awaiting for their day in court. The jury specifically found that AbbVie fraudently marketed Androgel by creating the condition “Low T.”
However, the verdict is also a win for AbbVie as the jury concluded that the label was adequate. Most pharmaceutical product liability claims pivot on the issue of whether the manufacturer of the prescription medicine properly warned of the risks associated with the product. Thus, the confusing message the jury has sent will cause attorneys for Androgel victims and AbbVie to speculate about future cases.
Androgel cases were consolidated into MDL 2545 In Re: Testosterone Replacement Therapy Products Liability Litigation in 2014. There are approximately 6,000 cases pending before Judge Matthew F. Kennelly. Androgel lawsuits involve heart attack, stroke, deep vein thrombosis and death. The next Androgel trial is set to start on August 28, 2017.
With the mixed verdict of the jury settlement values remain elusive. However,
We Can Help Still Help Androgel Users
James Esparza has been actively involved in Androgel lawsuits since 2014. If you or a loved one has suffered a heart attack, stroke, pulmonary embolism, deep vein thrombosis or death while using Androgel we can help. You can reach James at 1-800-745-4050.